



Committee for Orphan Medicinal Products

Public summary of positive opinion for orphan designation of tobramycin (liposomal) for the treatment of *Pseudomonas aeruginosa* lung infection in cystic fibrosis

On 11 April 2006, orphan designation (EU/3/06/366) was granted by the European Commission to EUCRO GmbH & Co. KG, Germany, for tobramycin (liposomal) for the treatment of *Pseudomonas aeruginosa* lung infection in cystic fibrosis.

The sponsorship was transferred to Axentis Pharma Limited, United Kingdom, in October 2008.

What is *Pseudomonas aeruginosa* lung infection in cystic fibrosis?

Cystic fibrosis is a hereditary (genetic) disease that affects the production of secretions (such as mucus) from the glands in the body. It affects the lungs and the digestive system (gut) in particular. Cystic fibrosis is caused by abnormalities in a gene called 'cystic fibrosis transmembrane conductance regulator' (CFTR). The CFTR gene is responsible for the production of CFTR, a protein that regulates the production of mucus and digestive juices by acting as a chloride ion channel to allow proper movement of salt and water in and out of certain cells in the lungs and other tissues. In patients with cystic fibrosis, there is an overproduction of mucus in the lungs and a reduced production of digestive juices from the pancreas (an organ near the stomach). This leads to long-term infection and inflammation of the lungs. *Pseudomonas aeruginosa* is a species of bacteria (micro-organisms that can cause certain types of infections). Chronic infection of the lung with *Pseudomonas aeruginosa* is a typical feature of cystic fibrosis. It can induce further damage to the lung tissue and respiratory insufficiency, which is life threatening.

What is the estimated number of patients affected by the condition * ?

At the time of designation *Pseudomonas aeruginosa* lung infection in cystic fibrosis affected approximately 1.3 in 10,000 people in the European Union (EU)*. This is based on the information provided by the sponsor and knowledge of the Committee for Orphan Medicinal Products (COMP). This is below the threshold for orphan designation which is 5 in 10,000. This is equivalent to a total of around 60,000 people.

What treatments are available?

At the time of submission of the application for orphan designation, *Pseudomonas aeruginosa* lung infection in cystic fibrosis was treated mostly with antibiotics (drugs that kill micro-organisms) and several antibiotics had been authorised for the condition in some countries in the Community. These could be taken in a number of ways such as by mouth, intravenous infusion or they could be inhaled as a fine mist of particles. Satisfactory argumentation has been submitted by the sponsor to justify the assumption that tobramycin (liposomal) might be of potential significant benefit for the treatment of *Pseudomonas aeruginosa* lung infection in cystic fibrosis, particularly because it could improve the

* Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed based on data from the European Union (EU 25), Norway, Iceland and Lichtenstein. This represents a population of 459,700,000 (Eurostat 2004).

long-term outcome of the patients and because it may contribute to the patient care. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

How is this medicine expected to work?

Tobramycin is an antibiotic with activity against a wide range microorganisms including *Pseudomonas aeruginosa*. Tobramycin is going to be administered directly into the lungs by inhalation. In addition, tobramycin is going to be incorporated in so called liposomes. The liposomes are structures made of phospholipids (the main components of the cell membrane) that create three-dimensional structures that can incorporate drugs. This liposomal formulation could then help tobramycin to be delivered in a more efficient way to the bacteria.

What is the stage of development of this medicine?

The effects of tobramycin (liposomal) were evaluated in experimental models.

At the time of submission of the application for orphan designation, no clinical trials in patients with *Pseudomonas aeruginosa* lung infection in cystic fibrosis were initiated.

Tobramycin (liposomal) was not authorised anywhere worldwide for the treatment of *Pseudomonas aeruginosa* lung infection in cystic fibrosis or designated as orphan medicinal product elsewhere for this condition, at the time of submission.

According to Regulation (EC) No 141/2000 of 16 December 1999, the Committee for Orphan Medicinal Products (COMP) adopted on 8 March 2006 a positive opinion recommending the grant of the above-mentioned designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- and either the rarity of the condition (affecting not more than five in 10,000 people in the Community) or the insufficient returns on investment

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

For more information:

Sponsor's contact details:

Axentis Pharma Limited

389 Nether Street

Finchley

London N3 1JN

United Kingdom

Telephone: +44 203 0511 714

Telefax: +44 203 0511 715

E-mail: board@axentispharma.com

Patients' associations contact points:

Vaincre la Mucoviscidose

181, rue de Tolbiac

75013 Paris

France

Telephone: +33 1 40 78 91 91

Telefax: +33 1 45 80 86 44

E-mail: info@vaincrelamuco.org

CFAI - Cystic Fibrosis Association of Ireland

CF House

24 Lower Rathmines Road

Dublin

Ireland

Telephone: +353 1 496 2433

Local call: 1890 311 211

Telefax: +353 1 496 2201

E-Mail: info@cfireland.ie

Mukoviszidose e.V.

Deutsche Gesellschaft zur Bekämpfung der Mukoviszidose, gemeinnütziger Verein

Bendenweg 101

53121 Bonn

Germany

Telephone: +49 22 89 87 800

Telefax: +49 22 89 87 80 77

E-mail: info@mukoviszidose-ev.de

**Translations of the active ingredient and indication in all EU languages
and Norwegian and Icelandic**

Language	Active Ingredient	Indication
English	Tobramycin (liposom al)	Treatment of <i>Pseudomonas aeruginosa</i> lung infection in cystic fibrosis
Czech	Tobramycin (liposomální)	Léčba plicních infekcí vyvolaných <i>Pseudomonádou aeruginosa</i> p i cystické fibróze
Danish	Tobramycin (liposom al)	Behandling af lungeinfektion med <i>Pseudomonas aeruginosa</i> ved cystisk fibrose
Dutch	Tobramycine (liposomal)	Behandeling van <i>Pseudomonas aeruginosa</i> longinfectie bij cystische fibrosis
Estonian	Tobramütsiin (liposom al)	<i>Pseudomonas aeruginosa</i> poolt põhjustatud kopsuinfektsiooni ravi tsüstilise fibroosi korral
Finnish	Tobramysiini (liposom al)	<i>Pseudomonas aeruginosa</i> aiheuttaman keuhkoinfektion hoito kystisessä fibroosissa
French	Tobramycine (liposom al)	Traitement des infections pulmonaires à <i>Pseudomonas aeruginosa</i> dans la mucoviscidose
German	Tobramycin (liposom al)	Therapie der <i>Pseudomonas aeruginosa</i> -Infektion der Lunge bei zystischer Fibrose
Greek	Τομπραμυκίνη λιποσωμική)	θεραπεία λοιμώξεων των πνευμόνων με <i>Pseudomonas aeruginosa</i> κατά την κυστική ίνωση
Hungarian	Tobramycin (liposzóm al)	<i>Pseudomonas aeruginosa</i> okozta tüdőfertőzés kezelése cisztikus fibrózisban
Italian	Tobramicina (liposomale)	Trattamento di infezione polmonare da <i>Pseudomonas aeruginosa</i> nella fibrosi cistica
Latvian	(Liposomu) tobram ns ic	<i>Pseudomonas aeruginosa</i> izrais tas plaušu infekcijas rstčšana cistisk s fibrozēs gad jum
Lithuanian	Tobramicinas (liposom)	Plau i infekcijos, sukeltos <i>Pseudomonas aeruginosa</i> , gydymas, sergant cistine fibroze
Polish	Tobramycyna (liposomalna)	Leczenie zapalenia p uc wywo anych przez <i>Pseudomonas aeruginosa</i> w przebiegu zw óknienia torbielowatego
Portuguese	Tobramicina (lipossómica)	Tratamento de infecção pulmonar por <i>Pseudomonas aeruginosa</i> na fibrosa quística
Slovak	Tobramycín (lipozomálny)	Ošetrovanie infekcií p úc s <i>Pseudomonas aeruginosa</i> pri cystickej fibróze
Slovenian	Tobramicin (liposomska)	Zdravljenje plju nice povzro ene s <i>Pseudomonasom aeruginosa</i> pri cisti ni fibrozi
Spanish	Tobramicina (liposomal)	Tratamiento de infecciones pulmonares por <i>Pseudomonas aeruginosa</i> en la fibrosis quística
Swedish	Tobramycin (liposom al)	Behandling av lunginflammation orsakad av <i>Pseudomonas aeruginosa</i> vid cystisk fibros
Norwegian	Tobramycin (liposom al)	Behandling av lungeinfeksjon forårsaket av <i>Pseudomonas aeruginosa</i> ved cystisk fibrose
Icelandic	Tobramýcín (í fitukorna)	Meðferð á <i>Pseudomonas aeruginosa</i> lungnasykingum í slímseigjusjúkdómi